Dr. Prebet is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 George St
Ste 786
New Haven, CT 06511Phone+1 203-785-5531
Education & Training
Université Claude Bernard LyonClass of 2000
Certifications & Licensure
CT State Medical License 2015 - 2025
Clinical Trials
- A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia Start of enrollment: 2016 Jul 21
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Start of enrollment: 2018 Oct 29
- Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Start of enrollment: 2020 Aug 04
- Join now to see all
Publications & Presentations
PubMed
- 93 citationsThe use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres
Blood Advances. 2018-07-24 - 298 citationsProtective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapyRuxanda Moschoi, Véronique Imbert, Marielle Nebout, Johanna Chiche, Didier Mary
Blood. 2016-07-14 - 280 citationsAcute myeloid leukemia, version 3.2019Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
Journal of the National Comprehensive Cancer Network. 2019-01-01
Abstracts/Posters
- The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceThomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Yale Cancer Center Researchers Investigate Inducing “Synthetic Lethality” in Two Blood and Bone CancersDecember 10th, 2019
Excess Iron in MDSOctober 7th, 2016
Supportive Care Remains Backbone of Treatment in MDSMay 1st, 2015- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
